By Dr. David LaMond, Medical Director, Blue Sky MD
One of the questions I hear most often, usually a few months into treatment, is some version of this: “Do I have to take this forever?”
It is a fair question. GLP-1 medications are expensive, insurance coverage comes and goes, and nobody likes the idea of a weekly shot for the rest of their life. Some patients stop because their plan drops coverage. Some stop because they reached their goal and feel ready. Some stop over the holidays because they want to eat normally for a few weeks.
My answer is that you can stop. But if you stop without a plan, most of the weight is likely to come back, and the research on that is very clear. The good news is that the people who keep their results tend to have a few things in common, and those things can be planned for.
What happens in the research
Two of the largest GLP-1 trials tested what happens when people stop.
In the STEP 1 trial, adults took semaglutide 2.4 mg (the Wegovy dose) for 68 weeks and then stopped. In the follow-up extension, one year later, they had regained about two-thirds of the weight they had lost. Their blood pressure, blood sugar and cholesterol improvements faded along with it.
The SURMOUNT-4 trial did the same thing with tirzepatide (Zepbound). Everyone took tirzepatide for 36 weeks and lost an average of about 21% of their body weight. Then half were switched to a placebo without knowing it. Over the next year, the placebo group regained about 14% of their body weight, while the group that stayed on tirzepatide lost another 5.5%. Only about 1 in 6 people who stopped kept at least 80% of their weight loss.
A follow-up analysis of that trial, published in JAMA Internal Medicine in November 2025, found that 82% of the people who stopped regained more than a quarter of the weight they had lost. The more they regained, the more of the health benefit they gave back: waist size, blood pressure, cholesterol and blood sugar all moved back toward where they started. These are the same heart, metabolic and other benefits that reach beyond the scale, and they are a big part of why I take stopping seriously.
These trials stopped the medication abruptly, and most participants had no structured plan for afterward. That is close to the worst case. But it is also what happens to many people in real life when coverage ends and the next refill simply does not come.
Why the weight comes back
Weight regain after stopping is driven far more by biology than by willpower.
When you lose a meaningful amount of weight, your body treats it as a threat. Leptin, the hormone fat cells use to tell your brain how much energy you have stored, drops. Hunger hormones rise. Your resting metabolism slows down, sometimes more than your new body size would predict. A well-known study in the New England Journal of Medicine found these hunger and hormone changes were still present a full year after weight loss.
A GLP-1 medication quiets that pressure while you are taking it. It slows stomach emptying, lowers appetite in the brain and improves how your body handles insulin. When the medication leaves your system, the pressure is still there, but nothing is holding it back. Patients describe it well: the “food noise” comes back. (I wrote more about how these medications act on cravings and the brain’s reward system in GLP-1s and dopamine.)
There is a second reason, and it is the one I worry about most. If someone loses weight quickly on a high dose and does not eat enough protein or lift anything heavy, a large share of what they lose can be muscle. In a STEP 1 sub-study that measured body composition, lean mass made up close to 40% of the weight lost. Muscle is where your body burns a lot of its energy and handles much of its blood sugar. Lose it, and you come off the medication with a slower metabolism than you started with. The weight that comes back tends to come back as fat. I explain this in more detail in when GLP-1 dosing goes too far.
Who is most likely to regain
From what I see in practice, the people who struggle most after stopping usually have some combination of these:
- They stopped abruptly, often at a high dose.
- They lost weight very fast and were eating very little.
- They did not do any strength training.
- They never changed what or how they eat, because the medication did the work for them.
- They have an untreated issue underneath, such as insulin resistance, poor sleep or a hormone deficiency.
The people who do well usually built habits while they were on the medication, not after.
How I help patients stop well
I do not think every patient needs to stay on a GLP-1 forever. For some people with severe obesity, diabetes or heart disease, long-term treatment is the right call, the same way we treat blood pressure long term. For others, a well-planned exit can work. Here is how I approach it.
1. Get to a stable, lower dose first
I have always preferred the lowest dose that works over the highest dose a patient can tolerate. I call it dosing to satiety, not starvation. If someone is already on a moderate dose and eating normal portions, coming off is much less of a shock than stepping down from a dose that had them barely eating. When it is time to stop, we usually taper over several weeks rather than stopping all at once.
2. Protect muscle the whole way through
This is where my Five Non-Negotiables come in: a daily protein target, eating enough calories to protect your metabolism, steps plus strength training, hydration, and regular coaching visits. Strength training two to four times a week is not optional for my patients. Neither is protein. Your coach sets your protein target and checks it at every visit as part of our medical weight loss program.
3. Measure, don’t guess
At Blue Sky MD we measure resting metabolism and body composition. Before someone comes off a GLP-1, I want to know how much muscle they have kept and what their metabolism is doing. If their resting metabolism has dropped, we work on that before stopping, not after.
4. Check hormones and insulin
Low testosterone in men and women, perimenopause, thyroid problems and high insulin can all make weight harder to keep off. If a deficiency is present, treating it can make maintenance much easier. In our own practice, patients whose testosterone deficiency is treated tend to keep more of their weight off. That is an observation from our patients, not a randomized trial, but it has been consistent enough over the years that I check for it in everyone. (Why lab testing matters for your weight loss goals explains which labs we run, and for women in menopause, I wrote about how hormone therapy may help tirzepatide work better.)
5. Plan for the first 3 to 6 months after stopping
This is when hunger returns. We schedule more frequent check-ins, weigh-ins and coaching in that window. If weight climbs past an agreed point, we talk about restarting at a low dose before the progress is lost. A low-dose restart is part of the plan, and I build it in from the start.
Early signs the weight is coming back
Weight rarely comes back all at once. In the first weeks after stopping, most people notice the same things in roughly the same order:
- You feel hungry between meals again, after months of not thinking about food.
- Portions creep up. The plate that used to leave you full now leaves room.
- Cravings for sweets and snacks return, often in the evening.
- The scale moves up 2 or 3 pounds and does not settle back down.
None of these is a reason to panic. All of them are a reason to call. A 5-pound regain is much easier to address than a 25-pound one, and the tools we use early (more protein, more structure, a closer look at sleep and stress, sometimes a low restart dose) work best when we use them early.
What a maintenance plan can look like
Not everyone needs the same exit. For some patients, the right plan is to stop completely after a careful taper. For others, the right plan is a low maintenance dose that keeps hunger manageable while they keep building muscle and habits. If you are weighing semaglutide against tirzepatide for that longer stretch, my tirzepatide vs semaglutide guide walks through how we choose.
What matters is that the decision is made on purpose, with numbers in front of us: your weight, your body composition, your resting metabolism and your labs. That is very different from running out of pens and hoping for the best.
If you lost coverage and have to stop
If your insurance dropped coverage and stopping was not your choice, do not wait until your last pen to make a plan. Call us while you still have medication left. That gives us time to taper, adjust your nutrition and training, and look at other options with you.
What I tell patients who ask “Do I have to take this forever?”
You do not have to take a GLP-1 forever. But you do have to take care of the problem it was treating, and for most people that problem does not go away when the prescription ends.
I think of it this way. The medication is a tool. It makes it much easier to lose weight and build better habits. The habits, the muscle you build and the issues we treat along the way are what keep the weight off. If those are in place, coming off is a decision you can make calmly. If they are not, the safest plan is a lower maintenance dose while we build them. That is what a good GLP-1 program should give you from the first visit.
If you are thinking about stopping, or you already have and the weight is creeping back, talk with your Blue Sky MD provider. New to Blue Sky MD? Start with our 2-minute health assessment.
This article is for general education and is not a substitute for individual medical advice. Talk with your provider before changing or stopping any medication.
References
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002. https://doi.org/10.1056/NEJMoa2032183 (body composition sub-study in the supplement)
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. https://doi.org/10.1111/dom.14725
- Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48. https://doi.org/10.1001/jama.2023.24945
- Horn DB, et al. Weight regain and cardiometabolic changes after tirzepatide withdrawal: post hoc analysis of the SURMOUNT-4 randomized clinical trial. JAMA Intern Med. Published online November 24, 2025. https://doi.org/10.1001/jamainternmed.2025.6112
- Sumithran P, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365:1597-1604. https://doi.org/10.1056/NEJMoa1105816